Clinical trial
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB…
NCT00291967 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00291967 |
|---|---|
| Title | Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants |
| Official title | Evaluate the Feasibility of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Vaccine Administered as a 3 Dose Primary Vaccination Course at 6, 10 & 14 Weeks of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Pertussis, Hepatitis B, Hib Diseases, Neisseria Meningitidis Serogroups A & C Diseases |
| Intervention type | Biological |
| Interventions | DTPw-HBV/Hib-MenAC conjugate vaccine |
| Enrollment | 525 |
| Start date | Nov 1, 2002 |
| First posted | Feb 15, 2006 |
| Last update posted | Dec 8, 2006 |
| Countries | Philippines |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: